LOGIN  |  REGISTER
Surmodics
Astria Therapeutics

Artivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023 | Last Trade: US$20.54 0.21 1.03

ATLANTA, April 10, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 22nd Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 8:45 a.m. ET on April 18, 2023.  

A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page.  An archived copy of the webcast will be available for 90 days on the same website. 

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stents and stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Contacts:

  
   

Artivion

 

Gilmartin Group LLC       

D. Ashley Lee

 

Brian Johnston / Lynn Lewis

Executive Vice President and

 

Phone: 332-895-3222

Chief Financial Officer

 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 770-419-3355

  

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB